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Purpose
The purpose of this study was to compare the clinical and functional outcomes in patients
with primary base of tongue (BOT) cancer who received definitive radiotherapy (RT) or sur-
gery followed by radiotherapy (SRT).   
Materials and Methods
Between January 2002 and December 2016, 102 patients with stage I-IVB primary BOT can-
cer underwent either definitive RT (n=46) or SRT (n=56), and treatment outcomes were com-
pared between two groups. The expression of p16 was also analyzed. 
Results
The RT group had more patients with advanced T stage (T3-4) disease (58.7% vs. 35.7%,
p=0.021) and who received chemotherapy (91.3% vs. 37.5%, p < 0.001) than the SRT
group. At a median follow up of 36.9 months (range, 3.3 to 181.5 months), the 5-year overall
survival (OS) and disease-free survival (DFS) were 75.5% and 68.7%, respectively. With 
respect to treatment group, the 5-year OS and DFS in the RT and SRT groups did not differ
significantly (OS, 68.7% vs. 80.5%, p=0.601; DFS, 63.1% vs. 73.1%, p=0.653). In multivari-
ate analysis, OS differed significantly according to p16 expression (p16-negative vs. p16-
positive; hazard ratio [HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853; p=0.033).
Regarding DFS, p16 expression (p16-negative vs. p16-positive; HR, 0.164; 95% CI, 0.045
to 0.598; p=0.006) showed a significant effect in multivariate analysis. Functional defects
(late grade  3 dysphagia or voice alteration) were more frequently reported in the SRT than
in the RT group (16.1% vs. 2.2%, p=0.021).   
Conclusion
Despite advanced disease, patients in the RT group showed comparable survival outcomes
and better functional preservation than those in the SRT group.
Key words
Base of tongue cancer, Radiotherapy, Surgery, 
Treatment outcome, Organ preservation 
Sangjoon Park, MD1
Yeona Cho, MD1
Jeongshim Lee, MD1
Yoon Woo Koh, MD, PhD2
Se-Heon Kim, MD, PhD2
Eun Chang Choi, MD, PhD2
Hye Ryun Kim, MD, PhD3
Ki Chang Keum, MD, PhD1
Kyung Ran Park, MD, PhD4
Chang Geol Lee, MD, PhD1
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  
+  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +
Correspondence: Chang Geol Lee, MD, PhD
Department of Radiation Oncology, 
Yonsei Cancer Center, Yonsei University 
College of Medicine, 50 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8114
Fax: 82-2-312-9033
E-mail: CGLEE1023@yuhs.ac
Received  October 18, 2017
Accepted  December 22, 2017
Published Online  December 26, 2017
Departments of 1Radiation Oncology, 
2Otorhinolaryngology, and 
3Medical Oncology, Yonsei University 
College of Medicine, Seoul, Korea, 
4Department of Radiation Oncology, 
University of Washington Medical Center,
Seale, WA, USA 
Introduction
Until recently, the treatment of base of tongue (BOT) can-
cer has been a challenge for head and neck surgeons, radia-
tion oncologists, and medical oncologists. Patients with this
cancer are often diagnosed in advance stages because of its
ambiguous symptoms [1]. In cases of radical surgery, serious
functional impairment occurs in the majority of cases; even
after radical resection, the recurrence rate is high [2,3].
The current standard for treatment of BOT cancer is either
surgery or definitive radiotherapy (RT) with or without con-
current chemotherapy [4,5]. However, no published random-
ized studies have directly compared the efficacy of these
treatment options due to the low incidence rate of BOT can-
cer. Therefore, the treatment method is determined accord-
ing to the preference of the patient and the physician
considering the cancer stage, possibility of complete excision,
and functional loss expected after treatment.
There have been considerable advances in RT and surgical
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techniques and both treatments are expected to provide bet-
ter results [6,7]. In this context, research is needed to deter-
mine the optimal treatment for primary BOT cancer.
The purpose of this study was to compare the clinical and
functional outcomes in patients with BOT cancer who 
received either definitive RT or surgery followed by postop-
erative RT (SRT).
Materials and Methods
1. Patients
Data from a total of 139 consecutive patients who received
definitive RT or postoperative RT after primary surgery for
BOT squamous cell carcinoma between January 2001 and 
December 2016, were retrospectively reviewed. Patients with
double primary cancer (n=4), distant metastasis (n=1), 
re-irradiation (n=2), incomplete RT (n=5), histologic type
other than squamous cell carcinoma (n=22), or without
image follow-up (n=3) were excluded, leaving 102 patients
included in the analyses. Pretreatment evaluation, including
a complete history and physical examination, endoscopic 
examination, computed tomography (CT), and magnetic res-
onance imaging was performed for every patient. Patients
were staged according to the 2010 American Joint Committee
on Cancer criteria (7th edition). Patients treated with defini-
tive RT were staged clinically, whereas those with primary
surgery were staged both pathologically and clinically. 
2. Treatments
When selecting the optimal treatment strategy in our insti-
tution, clinicians consider the tumor extent and location; pha-
ryngeal function; and patient age, medical co-morbidities,
and preferences. As a result, 56 patients received surgery fol-
lowed by postoperative RT (SRT group), while 43 patients
were treated with definitive RT (RT group). 
The surgical techniques included local or composite resec-
tion either by open approaches or by transoral robotic sur-
gery (TORS) using da Vinci Robot (Intuitive Surgical Inc.,
Sunnyvale, CA). In those who received surgery, neck dissec-
tion was performed on the involved side or both sides of the
neck. 
In every patient, CT-based RT planning was used and RT
was performed using either 3-dimensional conformal RT or
intensity-modulated RT (IMRT). The median RT doses were
63 Gy (range, 52 to 68.4 Gy) and 70 Gy (range, 63 to 76 Gy)
for the SRT and RT groups, respectively. The RT field was
defined as the primary tumor with sufficient margins and
both sides of the neck. Gross tumors or involved lymph
nodes were treated with 66-70 Gy, postoperative tumors or
nodal beds with 60-66 Gy, involved nodal stations with 
60-63 Gy, and uninvolved nodal stations with 45-50 Gy.
Concurrent chemotherapy was performed with either cis-
platin or cetuximab-based regimens. The induction chemo-
therapy regimen consisted of the combination of docetaxel,
cisplatin, 5-fluorouracil, or titanium silicate-1, and cisplatin.
3. Outcome assessment
Patients without follow-up imaging were censored from
the analysis. Treatment failures were defined as persistent or
recurrent loco-regional disease or distant metastases. The
date of tissue confirmation or imaging study showing evi-
dence of failure was considered the date of failure. Acute tox-
icities were defined as adverse events occurring within 90
days from the start of treatment, while late toxicities were
defined as those observed at least 90 days after the start of
treatment. The severity of toxicities was scored using Com-
mon Terminology Criteria for Adverse Events (CTCAE) ver.
4.0 and toxicities  grade 3 were recorded. Among late toxi-
cities, dysphagia and voice alteration  grade 3 were consid-
ered functional defects. The grades of dysfunction in swa-
llowing and speech were based on both clinician and patient
assessments and, if available, referred to the result of verbal
function tests such as the Korean version of the Boston Nam-
ing Test (K-BNT) or Motor Speech Treatment Protocol
(MSTP). For patients developing subjective swallowing dif-
ficulty, the swallowing test was performed with video
esophagofluoroscopy under the category of pharyngeal
phase and the presence or absence of aspiration.
4. Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics for Windows ver. 23.0 (IBM Corp., Armonk, NY). The
differences in characteristics and toxicities between the two
groups were compared using chi-square tests, and linear-
by-linear association analysis was performed to calculate the
linear relationship for more than two groups. We calculated
survival time from the date of diagnosis until death or the
most recent follow-up date. Survival curves were estimated
using the Kaplan-Meier method and were compared using
log-rank tests. Cox proportional hazards models were used
to assess the association of variables with survival. p-values
less than 0.05 were considered statistically significant.
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Table 1.  Patient and treatment characteristics
Characteristic Total (n=102) SRT (n=56) RT (n=46) p-value
Age, median (range, yr) 58 (36-96) 57 (36-77) 60 (37-96)
Age (yr)
 58 52 (51.0) 32 (57.1) 20 (43.5) 0.170
> 58 50 (49.0) 24 (42.9) 26 (56.5)
Sex
Female 17 (16.7) 13 (23.2) 4 (8.7) 0.050
Male 85 (83.3) 43 (76.8) 42 (91.3)
Performance status
ECOG PS 0-1 92 (90.2) 54 (96.4) 38 (82.6) 0.040
ECOG PS 2 10 (9.8) 2 (3.6) 8 (17.4)
T stage
1 27 (26.5) 18 (32.1) 9 (19.6) 0.029
2 28 (27.5) 18 (32.1) 10 (21.7)
3 19 (18.6) 8 (14.3) 11 (23.9)
4a 27 (26.5) 12 (21.4) 15 (32.6)
4b 1 (1.0) 0 ( 1 (2.2)
N stage
0 15 (14.7) 7 (12.5) 8 (17.4) 0.090
1 19 (18.6) 15 (26.8) 4 (8.7)
2a 7 (6.9) 5 (8.9) 2 (4.3)
2b 45 (44.1) 25 (44.6) 20 (43.5)
2c 16 (15.7) 4 (7.1) 12 (26.1)
Stage
I 3 (2.9) 1 (1.8) 2 (4.3) 0.393
II 7 (6.9) 5 (8.9) 2 (4.3)
III 14 (13.7) 10 (17.9) 4 (8.7)
IVA 77 (75.5) 40 (71.4) 37 (80.4)
IVB 1 (1.0) 0 ( 1 (2.2)
p16
(–) 17 (29.3) 11 (28.9) 6 (30.0) 0.933
(+) 41 (70.7) 27 (71.1) 14 (70.0)
RT dose, mean (range, Gy) 64.9 (52.0-76.0) 61.5 (52.0-68.4) 69.0 (63.0-76.0) < 0.001
RT modality
3D CRT 29 (28.4) 16 (28.6) 13 (28.3) 0.972
IMRT 73 (71.6) 40 (71.4) 33 (71.7)
Chemotherapy
No chemotherapy 39 (38.2) 35 (62.5) 4 (8.7) < 0.001
Concurrent 49 (48) 19 (33.9) 30 (65.2)
Induction+concurrent 14 (13.7) 2 (3.6) 12 (26.1)
Chemotherapy regimen
Erbitux based 6 (9.4) 0 ( 6 (14.3) 0.163
Platinum based 57 (89.1) 22 (100) 35 (83.3)
Both 1 (1.5) 0 ( 1 (2.4)
Values are presented as number (%) unless otherwise indicated. SRT, surgery followed by radiotherapy; RT, definitive radio-
therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; RT dose, radiotherapy dose; RT modality, 
radiotherapy modality; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy. 
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Results
1. Patient and treatment characteristics
Table 1 shows the patient and treatment characteristics.
The median age of the patients was 58 years (range, 36 to 96
years). A total of 92 patients (90.2%) had stage III-IV disease,
with 47 (46.1%) having T3-4 and 87 (85.3%) having nodal
positive (N1-3) disease. p16 expression status was available
in 58 patients (56.9%). Among these, 41 (70.7%) had p16-pos-
itive and 17 (29.3%) had p16-negative tumors.
The characteristics that differed by treatment group 
included sex, initial Eastern Cooperative Oncology Group
performance status (ECOG PS), T stage, RT dose, and che-
motherapy. More patients in the RT group were male (91.3%
vs. 76.8%, p=0.050), ECOG PS  2 (17.4% vs. 3.6%, p=0.040),
had T3-4 disease (58.7% vs. 35.7%, p=0.021), and received
concurrent chemotherapy (91.3% vs. 37.5%, p < 0.001) com-
pared to the SRT group. The mean RT dose was higher in the
RT group (69.0 Gy vs. 61.5 Gy, p < 0.001). The other charac-
teristics were well balanced between the two groups. 
A total of 56 patients received surgery on the primary
tumor. Among these, 20 (35.7%) were treated via TORS and
five (9%) underwent total glossectomy. Bilateral (n=24) or 
ipsilateral (n=36) neck dissection was performed in 60 
patients, including those with elective neck dissection after
definitive RT (n=5).
2. Survival outcome and prognostic factors
At a median follow-up of 36.9 months (range, 3.3 to 181.5
months), the overall Kaplan-Meier estimations of the 5-year
overall survival (OS) and disease-free survival (DFS) rates
for all patients were 75.5% and 68.7%, respectively (Fig. 1).
In univariate analysis, performance status (OS, p=0.010; DFS,
p=0.014), T stage (OS, p=0.022; DFS, p=0.005), RT modality
(OS, p=0.005; DFS, p=0.006), and p16 expression (OS,
p=0.003; DFS, p < 0.001) were identified as prognostic factors
related to both OS and DFS (Table 2). In multivariate analy-
sis, p16 expression was an independent factor for both OS
and DFS (p16-negative vs. p16-positive; OS: hazard ratio
[HR], 0.145; 95% confidence interval [CI], 0.025 to 0.853;
p=0.033; DFS: HR, 0.164; 95% CI, 0.045 to 0.598; p=0.006)
(Table 3).
3. Outcome comparisons according to treatment group 
There were no significant differences in the 5-year OS
(68.7% vs. 80.5%, p=0.601) and DFS (63.1% vs. 73.1%,
p=0.653) between treatment groups (Fig. 2). 
In the subgroup analysis of T3-4 patients, the 5-year OS
(58.1% vs. 64.9%, p=0.906) and DFS (48% vs. 63.5%, p=0.958)
showed no significant difference according to the treatment
group (Fig. 3).
Data were analyzed separately for 38 patients with p16-
positive disease. There was no significant difference in the 
5-year OS (100% vs. 93.8%, p=0.342) and DFS (90% vs. 88%,
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Fig. 1.  Five-year overall survival (A) and disease-free survival (B) for the entire study cohort.
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p=0.865) between the RT and SRT groups (Fig. 4).
4. Patterns of failure
During the follow-up period, treatment failure occurred in
10 and 13 patients in the RT and SRT groups, respectively.
Table 4 shows the patterns of failure and outcomes of salvage
treatment among the patients who experienced local and/or
regional failures. Among eight failures in the RT group, only
one patient received re-irradiation with concurrent chemo-
therapy; two were salvaged with neck dissection and two
with chemotherapy as the sole treatment. All of these 
patients died of disease (survival after recurrence, 3 to 15
months) except for one patient who was successfully sal-
vaged with neck dissection (survival after recurrence, 4
months). Among six failures in the SRT group, three patients
were salvaged with chemotherapy or re-irradiation and two
underwent surgical resection of recurrent primary tumors.
Four of those who received salvage treatment died of disease
progression (survival after recurrence, 3 to 16 months) and 
No. of
OS DFS
Variable patients (%) 5-Year HR  p-value 5-Year HR p-value(%) (95% CI) (%) (95% CI)
Age (yr)
 58 52 (51.0) 83.5 1.573 (0.707-3.501) 0.267 72.5 1.275 (0.634-2.564) 0.496
> 58 50 (49.0) 67.2 65.0
Sex
Female 17 (16.7) 92.3 2.935 (0.689-12.500) 0.145 84.6 3.718 (0.887-15.589) 0.073
Male 85 (83.3) 72.1 65.6
Performance status
ECOG PS 0-1 92 (90.2) 79.6 3.698 (1.369-9.987) 0.010 72.8 3.090 (1.260-7.579) 0.014
ECOG PS 2 10 (9.8) 36.0 30.5
T stage
T1-T2 55 (53.9) 89.2 2.671 (1.150-6.202) 0.022 81.7 2.963 (1.398-6.281) 0.005
T3-T4a/b 47 (46.1) 61.3 55.0
N stage
N0 15 (14.7) 82.5 1.036 (0.354-3.031) 0.948 74.3 1.346 (0.472-3.840) 0.579
N1-3 87 (85.3) 74.1 67.6
Stage
I-II 10 (9.8) 100.0 2.653 (0.359-19.621) 0.339 80.0 3.363 (0.459-24.655) 0.233
III-IV 92 (90.2) 73.2 67.3
p16
(–) 17 (29.3) 60.7 0.088 (0.017-0.450) 0.003 46.5 0.119 (0.036-0.391) < 0.001
(+) 41 (70.7) 95.2 88.3
Treatment
SRT 56 (54.9) 80.5 1.233 (0.562-2.704) 0.602 73.1 1.173 (0.585-2.351) 0.654
RT 46 (45.1) 68.7 63.1
RT dose 0.995 (0.943-1.050) 0.859 0.994 (0.948-1.042) 0.808
RT modality
3D CRT 29 (28.4) 62.1 0.304 (0.133-0.697) 0.005 51.7 0.369 (0.183-0.748) 0.006
IMRT 73 (71.6) 81.4 77.4
Chemotherapy
Not concurrent 39 (38.2) 74.3 0.750 (0.341-1.653) 0.476 69.6 0.882 (0.439-1.772) 0.725
Concurrent 63 (61.8) 76.3 68.2
Table 2. Univariate analysis for OS and DFS
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative
Oncology Group performance status; SRT, surgery followed by radiotherapy; RT, definitive radiotherapy; RT dose, radio-
therapy dose; RT modality, radiotherapy modality; 3D CRT, 3-dimensional conformal radiotherapy; IMRT, intensity-mod-
ulated radiotherapy.
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another died of bleeding after salvage surgery (survival after
recurrence, 3 months).
5. Toxicities and functional outcomes
The complications requiring surgical intervention are 
described in Table 5. Wound dehiscence, bleeding, infection,
No. of
OS DFS
Variable patients (%) 5-Year HR  p-value 5-Year HR p-value(%) (95% CI) (%) (95% CI)
Performance status
ECOG PS 0-1 53 (91.4) 91.2 6.465 (0.346-120.758) 0.211 82.3 2.507 (0.401-15.666) 0.326
ECOG PS 2 5 (8.6) 37.5 26.7
T stage
T1-T2 34 (58.6) 92.3 0.785 (0.129-4.780) 0.793 82.3 1.146 (0.313-4.202) 0.837
T3-T4a/b 24 (41.4) 79.5 69.5
p16
(–) 17 (29.3) 60.7 0.145 (0.025-0.853) 0.033 46.5 0.164 (0.045-0.598) 0.006
(+) 41 (70.7) 95.2 88.3
RT modality
3D CRT 11 (19.0) 81.8 0.237 (0.022-2.505) 0.231 72.7 0.489 (0.116-2.057) 0.326
IMRT 47 (81.0) 85.6 78.2
Table 3. Multivariate analysis for OS and DFS
OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative
Oncology Group performance status; RT modality, radiotherapy modality; 3D CRT, 3-dimensional conformal radiotherapy;
IMRT, intensity-modulated radiotherapy.
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Fig. 2.  Comparison of 5-year overall survival (A) and disease-free survival (B) between the definitive definitive radiotherapy
(RT) and surgery followed by radiotherapy (SRT) groups.
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Fig. 3.  Comparison of 5-year overall survival (A) and disease-free survival (B) between treatment groups in T3-4 patients.
SRT, surgery followed by radiotherapy; RT, definitive radiotherapy.
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1220 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2018;50(4):1214-1225
Pa
tie
nt
 
Ag
e 
St
ag
e
p1
6
Tr
ea
tm
en
t
M
od
ali
ty
Fa
ilu
re
 
St
ag
e a
t 
Tr
ea
tm
en
t a
fte
r 
Tr
ea
tm
en
t  
Cu
rre
nt
Su
rv
iv
al 
af
ter
  
No
.
(y
r)/
Se
x
sta
tu
s
pa
tte
rn
fa
ilu
re
re
cu
rre
nc
e
re
sp
on
se
sta
tu
s
re
cu
rre
nc
e (
m
o)
1
63
/M
T4
aN
2b
N/
A
CC
RT
IM
RT
R
N2
b
No
ne
N/
A
DO
D
3
2
81
/M
T4
aN
1
N/
A
RT
3D
 C
RT
L
T4
aN
0
No
ne
N/
A
DO
D
12
3
60
/M
T3
N0
N/
A
In
du
cti
on
+C
CR
T
3D
 C
RT
L, 
R
T2
N2
b
No
ne
N/
A
DO
D
6
4
50
/M
T4
aN
2b
N/
A
In
du
cti
on
+C
CR
T
3D
 C
RT
L
T4
aN
0
Ch
em
ot
he
ra
py
PD
DO
D
3
5
65
/M
T2
N2
b
Ne
ga
tiv
e
CC
RT
3D
 C
RT
R
N2
b
Ne
ck
 di
sse
cti
on
, c
he
m
ot
he
ra
py
PD
DO
D
15
6
58
/M
T4
bN
2c
N/
A
CC
RT
IM
RT
R,
 D
N2
bM
1
Ch
em
ot
he
ra
py
PD
DO
D
4
7
56
/M
T3
N2
cM
0
Ne
ga
tiv
e
CC
RT
IM
RT
R
N2
c
Ne
ck
 di
sse
cti
on
NE
D
AW
OD
7
8
53
/M
T3
N2
c
N/
A
In
du
cti
on
+C
CR
T
3D
 C
RT
R
N2
c
Ch
em
ot
he
ra
py
, s
alv
ag
e C
Cr
eR
T
PD
DO
D
15
9
74
/F
T3
N0
N/
A
SR
T
3D
 C
RT
R
N2
b
No
ne
N/
A
DO
D
3
10
38
/M
T2
N2
b
N/
A
SR
T
3D
 C
RT
L
T1
Sa
lva
ge
 su
rg
er
y
N/
A
DO
OC
3
11
41
/M
T2
N0
Ne
ga
tiv
e
SR
T
3D
 C
RT
L, 
R
T3
N2
b
Sa
lva
ge
 C
Cr
eR
T
PD
DO
D
10
12
53
/F
T1
N0
N/
A
SR
T
3D
 C
RT
L
T2
Ch
em
ot
he
ra
py
PR
DO
D
3
13
37
/M
T4
aN
1
N/
A
SR
T
IM
RT
L
T3
Sa
lva
ge
 su
rg
er
y
PD
DO
D
16
14
59
/M
T2
N1
N/
A
SR
T
3D
 C
RT
L, 
R
T4
aN
2b
Ch
em
ot
he
ra
py
N/
A
DO
D
5
Ta
bl
e 4
.F
ail
ur
e p
att
er
ns
 an
d o
ut
co
m
es
 of
 sa
lva
ge
 tr
ea
tm
en
ts
M
, m
ale
; N
/A
, n
ot
 av
ail
ab
le;
 C
CR
T, 
de
fin
iti
ve
 co
nc
ur
re
nt
 ch
em
or
ad
iot
he
ra
py
; IM
RT
, in
ten
sit
y-
m
od
ul
ate
d r
ad
iot
he
ra
py
; R
, re
gio
na
l fa
ilu
re
; D
OD
, d
ied
 of
 di
se
as
e;
RT
, d
efi
ni
tiv
e r
ad
iot
he
ra
py
; 3
D 
CR
T,
 3-
di
m
en
sio
na
l c
on
fo
rm
al 
ra
di
ot
he
ra
py
; L
, lo
ca
l f
ail
ur
e; 
PD
, p
ro
gr
es
siv
e d
ise
as
e; 
D,
 d
ist
an
t f
ail
ur
e; 
NE
D,
 n
o e
vid
en
ce
 of
di
se
as
e; 
AW
OD
, a
liv
e w
ith
ou
t d
ise
as
e; 
CC
re
RT
, r
e-i
rra
di
ati
on
 w
ith
 co
nc
ur
re
nt
 ch
em
ot
he
ra
py
; F
, fe
m
ale
; S
RT
, s
ur
ge
ry
 fo
llo
we
d 
by
 ra
di
ot
he
ra
py
; D
OO
C,
 d
ied
 of
ot
he
r c
au
se
;  P
R,
 pa
rti
al 
re
sp
on
se
.
VOLUME 50 NUMBER 4 OCTOBER 2018  1221
Sangjoon Park, Treatment Outcome of Base of Tongue Cancer
and flap necrosis were among the immediate complications,
whereas wound fistula, pharyngeal stenosis, and scar con-
tracture were considered delayed complications. The wound
complications were more frequent in the SRT group than in
the RT group (25% vs. 2.2%, p=0.001).
Table 6 shows the acute and late toxicities in accordance
with CTCAE ver. 4.0. There was no significant difference in
the rates of overall  grade 3 acute toxicities between treat-
ment groups (28.6% vs. 37%, p=0.271), while  grade 3 late
toxicities were more frequently observed in the SRT group
(20% vs. 2.2%, p=0.006). Functional defects (defined as late
grade  3 dysphagia or voice alteration) were more fre-
quently reported in the SRT group than in the RT group
(16.1% vs. 2.2%, p=0.021).
In surgery group, patients were sub-classified to open sur-
gery group and TORS group. The complications requiring
surgical intervention more frequently occurred in open sur-
gery group than TORS group. Similarly, open surgery group
reported more severe treatment-related late toxicities and
functional defect compared to TORS group. When compar-
ing the function of TORS group with that of RT group, only
one patient (5%) reported severe dysfunction and no signif-
Variable Total 
SRT (n=56)                              RT p-valuea)(n=102) Total (n=56) Open (n=36) TORS (n=20) (n=46)
Wound infection 1 (1.0) 1 (1.8) 1 (2.8) 0 ( 0 ( 0.001
Wound dehiscence 5 (4.9) 4 (7.1) 2 (5.6) 2 (10.0) 1 (2.2)
Wound bleeding 4 (3.9) 4 (7.1) 3 (8.3) 1 (5.0) 0 (
Wound fistula 2 (2.0) 2 (3.6) 2 (5.6) 0 ( 0 (
Pharyngeal stenosis 1 (1.0) 1 (1.8) 1 (2.8) 0 ( 0 (
Flap necrosis 5 (4.9) 5 (8.9) 5 (13.9) 0 ( 0 (
Scar contracture 3 (2.9) 3 (5.4) 3 (8.3) 0 ( 0 (
Table 5. Complications requiring surgical intervention
Values are presented as number (%). SRT, surgery followed by radiotherapy; RT, definitive radiotherapy; Open, open surgery
group; TORS, trans-oral robotic surgery group. a)p-value was calculated between SRT group and RT group. 
Toxicity Grade Total 
SRT (n=56)                              RT p-valuea)(n=102) Total (n=56) Open (n=36) TORS (n=20) (n=46)
Acute
Skin G3 8 (7.8) 1 (1.8) 0 ( 1 (5.0) 7 (15.2) 0.271
Mucositis G3 21 (20.6) 8 (14.3) 3 (8.3) 5 (25.0) 13 (28.3)
Fatigue G3 1 (1.0) 0 ( 0 ( 0 ( 1 (2.2)
Voice alteration G3 1 (1.0) 1 (1.8) 1 (2.8) 0 ( 0 (
G4 5 (4.9) 5 (8.9) 5 (13.9) 0 ( 0 (
Dysphagia G3 4 (3.9) 4 (7.1) 2 (5.6) 2 (10.0) 0 (
Late
Xerostomia G3 1 (1.0) 1 (1.8) 1 (2.8) 0 ( 0 ( 0.006
Osteoradionecrosis G3 3 (2.9) 3 (5.4) 2 (5.6) 1 (5.0) 0 (
Dysphagia G3 3 (2.9) 3 (5.4) 3 (8.3) 0 ( 0 (
Voice alteration G3 5 (4.9) 4 (7.1) 3 (8.3) 1 (5.0) 1 (2.2)
G4 5 (4.9) 5 (8.9) 5 (13.9) 0 ( 0 (
Functional defect
Dysphagia  G3 3 (2.9) 3 (5.4) 3 (8.3) 0 ( 0 ( 0.250
Voice alteration  G3 10 (9.8) 9 (16.1) 8 (22.2) 1 (5.0) 1 (2.2) 0.021
Table 6. Toxicities and pharyngeal function after treatment 
Values are presented as number (%). SRT, surgery followed by radiotherapy; RT, definitive radiotherapy; Open, open surgery
group; TORS, trans-oral robotic surgery group; G, grade. a)p-value was calculated between SRT group and RT group.
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icant difference was noted compared to the RT group (TORS
group vs. RT group, 5% vs. 2.2%, p=0.517).
Discussion
BOT cancer is a relatively rare disease, with a reported age-
standardized incidence rate of 0.5/100,000 person-year in 
developed countries [8], though it is the second most com-
mon primary site in oropharyngeal cancer (OPC). The prog-
nosis of BOT cancer is worse than that of tonsillar cancer, the
most common OPC [9]. However, until now, most evidence
has been provided by studies of OPC, which include more
cases of primary tonsillar cancer than primary BOT cancer.
Several studies have reported treatment results only for BOT
cancer but did not directly compare treatment outcomes 
between surgery and RT. 
Historically, surgical treatment, which had been consid-
ered the preferred treatment, had the advantage of being able
to remove the tumor curatively; however, it reportedly
causes serious dysfunction and frequent loco-regional recur-
rence. Surgery alone is considered an appropriate treatment
for early-stage disease, but treatment outcomes for locally
advanced disease were not satisfactory [2,3]. To achieve both
tumor control and functional preservation, definitive RT was
considered as primary treatment. Several studies reported
favorable outcomes after definitive RT when compared to
the historical results of primary surgery [10-12]. However,
although offering better functional preservation, external
beam RT alone showed poor oncologic outcomes in locally
advanced stage disease [10,13]. Consequently, to improve
tumor control, several methods have been investigated, 
including the concurrent use of chemotherapy for radiosen-
sitization [14], altered daily fractionation with hyperfraction-
ation [15], interstitial brachytherapy, and external beam RT
boost [1,16].
Recently, minimally-invasive transoral endoscopic surgery
(TES) has made it possible to treat OPC with better functional
preservation than that of traditional open approaches.
Among TES approaches, transoral laser microsurgery
showed excellent oncological and functional outcome in
head and neck cancer [17]; a more recent technique, TORS
has demonstrated its feasibility for the removal of the tumors
in oropharyngeal region [18]. In addition, the dose confor-
mality of radiation therapy has improved and the introduc-
tion of IMRT has made it possible to deliver the higher doses
needed to control gross tumors while preserving unaffected
organs near the target.
Another remarkable finding in cancer biology was the 
report that human papillomavirus (HPV)positive OPC has
a quite different etiology and prognosis from those of HPV-
negative counterparts [19]. Although not yet fully explored,
HPV-associated tumors are suspected to be caused by E6 and
E7 viral oncoproteins that bind to and consequently inacti-
vate the p53 tumor suppressor gene and retinoblastoma pro-
tein (pRB), resulting in the malignant transformation of
HPV-infected cells. As a result, the biology of HPV-positive
tumors is distinct from that of HPV-negative tumors, featur-
ing p16 up-regulation due to reduced negative feedback
from the pRB pathway [20-22]. The better prognosis of HPV-
positive tumors was noted after treatment including RT as
well as surgery [23,24]. A possible explanation for the impro-
ved survival in HPV-positive tumors after RT might be the
functional TP53 presence in HPV-positive tumor, which
makes the tumor more susceptible to radiation-induced
apoptosis, in contrast to HPV-negative, tobacco-associated
tumors [25]. The functional preservation of the pharynx and
tongue is especially important for patients with HPV-posi-
tive OPCs who are expected to survive longer. However,
studies on the survival and functional outcomes of BOT can-
cer lack data on HPV infection status. In the current study,
multivariate analysis revealed that p16 expression status, in
other words, HPV infection status, was the only independent
factor for survival.
This study compared the treatment and functional out-
comes of patients treated with definitive RT or surgery fol-
lowed by adjuvant RT with modern techniques in the same
institution. In addition, the HPV infection status was 
reported in more than half of the patients. A comparison 
between the two treatment groups showed that the patient
and treatment characteristics did not differ significantly 
except for the proportion of locally advanced disease, the
proportion of patients with poor performance status, the pro-
portion of men, and the use of chemotherapy, which were
higher in the RT group. The higher proportion of advanced
disease and poor performance status in the RT group could
be explained by the fact that curative resection is not feasible
for these patients; in these cases, definitive RT might be pre-
ferred. The addition of concurrent chemotherapy to RT was
proven to be superior to RT alone in the early 2000s [26,27];
we have used concurrent chemotherapy routinely during 
definitive RT with some exception (e.g., old age, medical con-
dition, patient denial). However, the benefit of chemotherapy
during adjuvant RT is not clear except for cases with adverse
pathologic features [28,29]. Therefore, patients undergoing
surgery in our institution received chemotherapy only if 
adverse features were reported. When comparing the treat-
ment outcomes of the two groups, there was no statistically
significant difference in OS or DFS. In addition, subgroup
analysis of patients with T3-4 and HPV-positive disease did
not reveal any significant differences between the two treat-
ment groups. These results suggest the possibility that RT
VOLUME 50 NUMBER 4 OCTOBER 2018  1223
Sangjoon Park, Treatment Outcome of Base of Tongue Cancer
could be considered as the preferred treatment for patients
with locally advanced stage disease expected to have severe
morbidity after surgery and for patients with HPV-positive
disease expected to have a favorable prognosis regardless of
treatment modality. Regarding toxicities and functional out-
comes, late toxicities above grade 3 occurred more frequently
in the SRT group and voice alteration above grade 3 was also
frequently reported in the SRT group, which implies that bet-
ter functional preservation is expected by definitive RT com-
pared to surgery, even in more advanced disease. However,
when SRT group was sub-classified into open surgery group
and TORS group, the wound complications, late toxicities
were less frequently reported in TORS group than open sur-
gery group, and the functional outcomes of TORS group
were comparable to the RT group. Nevertheless, caution
should be exercised before deriving any conclusions based
on these findings, because only 20 patients underwent TORS
in our cohort; among them, 16 had T1-2 disease.
Several limitations should be taken into account, stemming
from the retrospective nature of this study. The major limi-
tation was the heterogeneous radiation doses and chemo-
therapy regimens. The radiation doses differed considerably
within both treatment groups (SRT group, 52-68.4 Gy; RT
group, 63-76 Gy). Additionally, the chemotherapy schedules
and regimen themselves were heterogeneous. In addition,
our study cohort was relatively small, as the incidence of pri-
mary BOT cancer is low.
Despite these limitations, in the absence of a randomized
controlled trial with large population of BOT cancer, this is
one of the largest single-institution studies to compare 
patients treated with primary surgery and definitive RT
treated contemporarily. The results of current study suggest
that definitive RT showed no significant differences in sur-
vival, with better function when compared to surgery fol-
lowed by postoperative RT, despite the fact that the pro-
portion of patients with locally advanced stage disease was
higher in the RT group. Definitive RT might be considered
as a preferred primary treatment option, especially for HPV-
positive patients who are expected to have a long-life 
expectancy or for those with locally advanced stage disease
in which surgical resection may result in severe defects.
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